In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emily Hayes

San Francisco, CA
Emily Hayes is a writer/editor with over 20 years’ experience in medical journalism, including magazines for specialist clinicians, government health publications, business newswires and pharma trade press.  Her educational background lies in journalism and political science. Emily has dual citizenship and has experience working in the UK and US. Since 2008, she has been a senior writer on staff with “The Pink Sheet,” working out of her home base in biopharma hub San Francisco. She enjoys covering drug development, with special areas of focus in cancer, particularly immunotherapy, and cardiology/metabolics. She covers major scientific meetings regularly, including the American Society of Clinical Oncology, and appreciates interactions with key opinion leaders while interpreting drug trial results. In her free time, she is a professional jazz/blues/country vocalist.
Advertisement
Set Alert for Articles By Emily Hayes

Latest From Emily Hayes

Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer

In addition to Opdivo, three other PD-1/L1 inhibitors are in late-stage development for a high-unmet need disease, including Roche's Tecentriq, which will be filed as soon as possible.

Research & Development ImmunoOncology

Biohaven Readies Glutamate Modulator BHV-0223 For Phase III In Anxiety

Glutamate modulators could play a role in a range of central nervous system disorders, including social anxiety, amyotrophic lateral sclerosis. Biohaven's first – a reformulation of a generic ALS drug – could be on the market in two years.

Research & Development Neurology

Private Longeveron Bets On Stem Cells For Inflammation, Aging Diseases

Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.

StartUps and SMEs Business Strategies

Regeneron's Extended Eylea Dosing Plan Suffers US FDA Delay

Competitors are moving forward on wet AMD products with longer dosing intervals, with Novartis close to filing with FDA.
FDA Regulation

Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro

The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.

Rare Diseases Pharmacy Benefit Management

Portola's Rocky Commercial Transition On Show In Q2, With No CEO

Company reported only $33,000 in sales for late anticoagulant market entrant Bevyxxa and $2.2m for the antidote Andexxa, leaving a lot of challenges ahead after the retirement of CEO Bill Lis, effective Aug. 1.

Sales & Earnings Launches
See All
Advertisement
UsernamePublicRestriction

Register